CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A

被引:21
作者
Fukami, T.
Nakajima, M. [1 ]
Sakai, H.
McLeod, H. L.
Yokoi, T.
机构
[1] Kanazawa Univ, Grad Sch Med Sci, Div Pharmaceut Sci, Dept Drug Metab & toxicol, Kanazawa, Ishikawa 920, Japan
[2] Washington Univ, Dept Med, St Louis, MO 63130 USA
关键词
CYP2A6; CYP2A7; deletion allele; genetic polymorphism;
D O I
10.1038/sj.tpj.6500390
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Human cytochrome P450 (CYP) 2A6 metabolizes nicotine to cotinine. Genetic polymorphisms of CYP2A6 contribute to the interindividual variability of nicotine metabolism. We encountered some subjects possessing two copies of the CYP2A6 gene, although they were genotyped as heterozygotes of the CYP2A6*4A allele ( entire CYP2A6 gene deleted allele). From the subjects, we found CYP2A7 polymorphic alleles (CYP2A7*1B, CYP2A7*1C, and CYP2A7*1D) in which the sequences in the 3'-flanking region were converted to the corresponding CYP2A6 sequences, being confused with the CYP2A6*4A. These allele frequencies in European-Americans (n = 187) were 1.3, 2.1, 0.3%, respectively, but these were very rare in African-Americans (n = 176), Japanese (n = 184), and Koreans ( n 209). By an improved genotyping method, the allele frequency of CYP2A6*4A of 3.7% in European-Americans was corrected to 0%. The comprehensible and reliable genotyping method developed in this study would be useful to evaluate associations between the genotype and phenotype.
引用
收藏
页码:401 / 412
页数:12
相关论文
共 35 条
  • [1] Ariyoshi N, 2002, CANCER EPIDEM BIOMAR, V11, P890
  • [2] Identification of deletion-junction site of CYP2A6*4B allele lacking entire coding region of CYP2A6 in Japanese
    Ariyoshi, N
    Sekine, H
    Nakayama, K
    Saito, K
    Miyamoto, A
    Kamataki, T
    [J]. PHARMACOGENETICS, 2004, 14 (10): : 701 - 705
  • [3] Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C
    Ariyoshi, N
    Takahashi, Y
    Miyamoto, M
    Umetsu, Y
    Daigo, S
    Tateishi, T
    Kobayashi, S
    Mizorogi, Y
    Loriot, MA
    Stücker, I
    Beaune, P
    Kinoshita, M
    Kamataki, T
    [J]. PHARMACOGENETICS, 2000, 10 (08): : 687 - 693
  • [4] EXPRESSION AND ALTERNATIVE SPLICING OF THE CYTOCHROME-P-450 CYP2A7
    DING, SH
    LAKE, BG
    FRIEDBERG, T
    WOLF, CR
    [J]. BIOCHEMICAL JOURNAL, 1995, 306 : 161 - 166
  • [5] Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers
    Fujieda, M
    Yamazaki, H
    Saito, T
    Kiyotani, K
    Gyamfi, MA
    Sakurai, M
    Dosaka-Akita, H
    Sawamura, Y
    Yokota, J
    Kunitoh, H
    Kamataki, T
    [J]. CARCINOGENESIS, 2004, 25 (12) : 2451 - 2458
  • [6] A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity
    Fukami, T
    Nakajima, M
    Higashi, E
    Yamanaka, H
    McLeod, HL
    Yokoi, T
    [J]. BIOCHEMICAL PHARMACOLOGY, 2005, 70 (05) : 801 - 808
  • [7] Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity
    Fukami, T
    Nakajima, M
    Higashi, E
    Yamanaka, H
    Sakai, H
    McLeod, HL
    Yokoi, T
    [J]. DRUG METABOLISM AND DISPOSITION, 2005, 33 (08) : 1202 - 1210
  • [8] A novel polymorphism of human CYP2A6 gene CTP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo
    Fukami, T
    Nakajima, M
    Yoshida, R
    Tsuchiya, Y
    Fujiki, Y
    Katoh, M
    McLeod, HL
    Yokoi, T
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (06) : 519 - 527
  • [9] Goodz SD, 2002, METHOD ENZYMOL, V357, P59
  • [10] Komatsu T, 2000, DRUG METAB DISPOS, V28, P1457